Loading clinical trials...
Loading clinical trials...
An Open-label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of CREPT-618 in Patients With Locally Advanced Hepatocellular Carcinoma
Conditions
Interventions
gene therapy
Locations
1
China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
Start Date
September 15, 2025
Primary Completion Date
August 15, 2026
Completion Date
September 15, 2027
Last Updated
January 23, 2026
NCT07469319
NCT07291076
NCT07365930
NCT07039201
NCT07150624
NCT07070076
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions